1. Home
  2. GRI vs CETX Comparison

GRI vs CETX Comparison

Compare GRI & CETX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$1.98

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Logo Cemtrex Inc.

CETX

Cemtrex Inc.

HOLD

Current Price

$2.60

Market Cap

3.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRI
CETX
Founded
2018
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
3.5M
IPO Year
N/A
1998

Fundamental Metrics

Financial Performance
Metric
GRI
CETX
Price
$1.98
$2.60
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$22.50
N/A
AVG Volume (30 Days)
178.3K
140.1K
Earning Date
11-14-2025
12-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,095,551.00
Revenue This Year
N/A
$19.77
Revenue Next Year
N/A
$15.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.50
52 Week Low
$1.10
$2.50
52 Week High
$16.92
$57.75

Technical Indicators

Market Signals
Indicator
GRI
CETX
Relative Strength Index (RSI) 54.38 35.87
Support Level $1.77 $2.86
Resistance Level $2.29 $3.42
Average True Range (ATR) 0.18 0.42
MACD 0.02 -0.08
Stochastic Oscillator 56.34 4.41

Price Performance

Historical Comparison
GRI
CETX

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

About CETX Cemtrex Inc.

Cemtrex Inc is a multi-industry technology company. It has expanded in a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security system. The company's operating segment includes, Security segment, Industrial Services segment and the corporate segment. The security segment provides end to end security to all industrial, corporate and governmental security via owned subsidiary Vicon. Whereas AIS part Industrial Service Segment is expertise services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. It generates maximum revenue from the Industrial Service Segment. It geographically operates in USA, UK and India, with maximum of revenue from USA.

Share on Social Networks: